Fidaxomicin for Clostridium difficile infection [5]

New England Journal of Medicine

Volumn 364, Issue 19, 2011, Pages 1875-1876

  Linsky, Amy ^a   Gupta, Kalpana ^a   Hermos, John A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; PROTON PUMP INHIBITOR; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; LETTER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENCE RISK; RECURRENT DISEASE; BLOOD; CLASSIFICATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTION; IMMUNOLOGY; MICROBIOLOGY; NOTE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; HUMANS; RECURRENCE; VANCOMYCIN; PROTON PUMP INHIBITORS;

EID: 79955895214     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1102685     Document Type: Letter

References (4)

1. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
2. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772-8. [Erratum, Arch Intern Med 2010;170:1100.]
3. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007;64:2359-63. (Pubitemid 350174708)
4. Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, Konikoff F. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007;9: 173-7. (Pubitemid 46111602)